MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. EBITDA 2011-2026 | ZOM
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -82.3 M | -49.5 M | -30.8 M | -21.5 M | -21.1 M | 17.1 M | -19 M | -16.4 M | -7.97 M | -54.5 K | -42.4 K | -77.5 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.1 M | -82.3 M | -19.3 M |
Quarterly EBITDA Zomedica Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.1 M | -7.53 M | -64 M | - | -7.02 M | -24.7 M | -10.1 M | - | -5.75 M | -6.57 M | -7.35 M | - | -6.48 M | -5.72 M | -4.23 M | - | -6.35 M | -5.27 M | -3.81 M | - | -4.92 M | -5.22 M | -2.26 M | - | -2.57 M | -2.11 M | -11.4 M | - | -1.64 M | -3.94 M | -1.97 M | - | -2 M | -1.5 M | -1.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.5 M | -64 M | -7.86 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Drug manufacturers industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-40 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-23.6 M | - | 0.86 % | $ 117 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
3.06 M | $ 4.06 | 4.1 % | $ 57.1 M | USA |
 |
Catalent
CTLT
|
-260 M | - | - | $ 11.5 B | USA |
 |
Cronos Group
CRON
|
-176 M | $ 2.68 | 3.08 % | $ 1.37 B |  Canada |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
6.82 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-65.5 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
-39.7 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
2.23 B | $ 5.63 | 1.53 % | $ 2.05 B | Canada |
 |
Organogenesis Holdings
ORGO
|
12.3 M | $ 2.35 | 0.86 % | $ 309 M | USA |
 |
Canopy Growth Corporation
CGC
|
-95.6 M | $ 1.19 | -2.87 % | $ 128 M | Canada |
 |
Pacira BioSciences
PCRX
|
5.41 M | $ 24.51 | -3.35 % | $ 1.13 B | USA |
 |
Harrow Health
HROW
|
31.8 M | $ 39.7 | 2.45 % | $ 1.46 B | USA |
 |
Jupiter Wellness
JUPW
|
654 K | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-142 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.57 M | $ 1.14 | -36.67 % | $ 1.41 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.45 | 0.7 % | $ 402 M | Canada |
 |
Tilray
TLRY
|
-1.37 B | $ 6.75 | -2.74 % | $ 4.17 B | Canada |
 |
Evolus
EOLS
|
-25.2 M | $ 5.3 | -0.19 % | $ 342 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.51 | -1.31 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-601 M | $ 8.03 | -0.74 % | $ 411 M | USA |
 |
Veru
VERU
|
-36.6 M | $ 2.32 | 0.43 % | $ 313 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-100 M | - | - | $ 193 M | Canada |
 |
Viatris
VTRS
|
3.51 B | $ 14.59 | -1.08 % | $ 17.5 B | USA |
 |
ProPhase Labs
PRPH
|
28.3 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
-2.86 M | $ 1.01 | - | $ 4.36 M | USA |
 |
Assertio Holdings
ASRT
|
8.47 M | $ 18.04 | 0.11 % | $ 116 M | USA |
 |
PetIQ
PETQ
|
81.6 M | - | 1.64 % | $ 400 M | USA |
 |
Solid Biosciences
SLDB
|
-178 M | $ 7.92 | -3.65 % | $ 693 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 7.21 | -0.55 % | $ 285 M | USA |
 |
Radius Health
RDUS
|
-53.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
4.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-22.3 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 1.02 | -2.86 % | $ 50.9 M | USA |
 |
PLx Pharma
PLXP
|
-40.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.39 | 3.35 % | $ 86.3 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-2.5 M | $ 0.87 | 1.99 % | $ 31.3 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-1.74 M | $ 0.61 | 1.65 % | $ 2.62 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.01 M | $ 2.19 | 0.46 % | $ 25.3 M | USA |